Evotec Completes Divesture of Chemical Development Business to Aptuit
News Dec 03, 2007
Evotec AG has announced that it has completed the sale of its Chemical Development Business to Aptuit, Inc. for a total consideration of £ 31.5 million (approx. EUR 44 million) effective November 30, 2007.
This divestiture allows Evotec to focus even more on its strategy to become an emerging pharmaceutical company providing high-value research results to its partners through discovery collaborations and partnering of pre-clinical and clinical programs developed internally. Following this divestiture, the proposed acquisition of Renovis, with an expected closing early next year, will be an important next step in building a leading CNS com-pany.
Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: “Evotec has decided to focus on core competencies that are important for high-value proprietary research and collaborations and to divest businesses that are not core to this strategy. We have successfully executed on this plan during the recent months and our increased cash resources put us in a very strong position to leverage our clinical assets.
We are pleased to hand-over to Aptuit a well established business and thank all the transfer-ring employees for their hard work over the years.”
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE